![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, July 31, 2019 12:40:05 PM
The nearest competitor for site drug delivery is
RenovoRX
They use an FDAapproved double balloon catheter Renovocath to inject gemcitabine +nab-paclitaxel, inside of a PC vein of their choosing. To be used as part of the front line induction treatment for newly diagnosed patients. In Phase 2 CTs it has yielded 22.4 month average overall survival. Overall survival for Chemo+radiation+Renovocath at 24 months 66.7%, and 5% for Chemo+radiation alone. They are now in Phase 3 (NCT03257033), involving 300 patients, and have funding.
If one wants to get excited over direct site drug injection, then there it is with RenovoRX. Shall we now make a few comparisons?
Renovocath front line treatment (larger potential patient population). CIAB second line treatment.
Renovocath delivering the front line drug therapy of gemcitabine +nab-paclitaxel, where both drugs are 100% already in the activated state. No need to encapsulate magic cells. PMCB's treatment hopes enough inactive Ifosfamide by random chance alone flows into a CIAB, and becomes activated.
Neither claims to treat metastatic PC cancer. Where 80% of newly diagnosed patients have metastasis. Although since both treatments will have drugs that go systemic, it seems the protocols in NCT03257033, will more likely control/slow down metastasis, than the Kenny wonder protocol using Metronomic Ifosfamide.
Then we have Kenny in his Kenny world of dreams, claiming PMCB will skip Phase 1, 2a which would be FDA firsts, and 6 months later, any promising results will yield breakthrough status, and an instant NDA wave into the market. Meanwhile despite very favorable results, back in the real world RenovoRX has spent years in CTs starting in Phase 1, and now in Phase 3. The Phase 3 CT started 12-Mar-2018. Expect top line results in Sep 2022. Study completion 2023.
Yes, Kenny and PMCB are years behind. The last 8 yrs of Kenny PR pumps, stumbling around not knowing what he was doing, have ensured it. So again, why is there suppose to be excitement over CIAB+Metronomic chemo treating PC, with no mythical IND submitted? Why will the whole Pharma sector come knocking on Kenny's door, IF the mythical IND ever is submitted?
Disclosure: I have no shares or affiliation with RenovoRX.
The Jewel of the Mind is Colored with the Hue of what it Imagines
Recent PMCB News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM